The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Revised Response Criteria for Malignant Lymphoma

Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,452

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Hallek, M. J., Cheson, B. D., Catovsky, D., Caligaris‐Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,782

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Döhner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,686

International uniform response criteria for multiple myeloma

Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445

Multiple Myeloma

Palumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,382

Multiple myeloma

Raje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137

Initial genome sequencing and analysis of multiple myeloma

Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C. L., Schinzel, A. C., Harview, C. L., Brunet, J.-P., Ahmann, G. J., Adli, M., et al. (2011) · Nature · doi:10.1038/nature09837 · Cited by 1,457

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

Baccarani, M., Cortes, J. E., Pane, F., Niederwieser, D. W., Saglio, G. N., Apperley, J. F., Cervantes, F., Deininger, M. W., Gratwohl, A. A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,276

Loss of Serum and Glucocorticoid-Regulated Kinase 3 (SGK3) Does Not Affect Proliferation and Survival of Multiple Myeloma Cell Lines

Hausmann, S., Brandt, E., Köchel, C., Einsele, H., Bargou, R. C., Seggewiß-Bernhardt, R., & Stühmer, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122689 · Cited by 5

The regulation of human organic anion transporter 4 by insulin-like growth factor 1 and protein kinase B signaling

Yu, Z., Wang, H., & You, G. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115702 · Cited by 4

A rapid and accurate method for evaluating the degradation of pan-Akt in cells by PROTACs using NanoLuc luciferase

Ji, X., Miao, L., Wu, Y., Zhao, T., Si, Y., Tan, X., Zhou, Q., Zuo, R., Pei, J., Wu, J., et al. (2024) · Biology Methods and Protocols · doi:10.1093/biomethods/bpae014 · Cited by 5

Sulforaphane inhibits multiple myeloma cell-induced osteoclast differentiation and macrophage proliferation by elevating ferroportin1

Sun, W., Sun, J., Hu, W., Luo, C., Lu, Z., He, F., Zhao, H., Zeng, X., Cao, D., Li, J., et al. (2024) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-024-04736-7 · Cited by 4

Computational study on subfamilies of piperidine derivatives: QSAR modelling, model external verification, the inter-subset similarity determination, and structure-based drug designing

Sadeghi, F., Afkhami, A., Madrakian, T., & Ghavami, R. (2021) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2021.1891568 · Cited by 4

The role of Capon in multiple myeloma

Shen, Y., Liu, H., Gu, S., Wei, Z., & Liu, H. (2017) · Tumor Biology · doi:10.1177/1010428317713674 · Cited by 4

Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma

Wang, C., He, Z.-M., Shi, Y.-Y., Zhang, L., Chen, Y., Chen, Z., & Yu, L. (2017) · Hematology · doi:10.1080/10245332.2016.1234186 · Cited by 4

Resistance Mechanisms to Novel Therapies in Myeloma

Wallington-Beddoe, C. T., & Coghlan, D. W. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.77004 · Cited by 3

Targeting serine metabolism vulnerability in omipalisib-resistant acute myeloid leukemia with phosphoglycerate dehydrogenase inhibitors

Tseng, C.-Y., Fu, Y.-H., Ou, D., Hou, H., Chien, H., & Lin, L. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118689 · Cited by 2

Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial

Zhang, P., Sun, T., Wang, Y., Wei, L. I., Tong, Z., Phadke, S. D., Feinstein, T. M., Ma, W., Guo, P., Zhang, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69225-2 · Cited by 2

Drug Resistance Analysis of Pancreatic Cancer Based on Universally Differentially Expressed Genes

Xia, J., LinYong, Z., Zhang, H., Fan, Q., Liu, H., Wang, O., & Yan, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26093936 · Cited by 2

Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma

Wang, H., Baladandayuthapani, V., Wang, Z., Lin, H. Y., Berkova, Z., Davis, R. E., Yang, L., & Orlowski, R. Z. (2017) · Oncotarget · doi:10.18632/oncotarget.23017 · Cited by 2

Novel Targets in Multiple Myeloma

Chari, A. (2015) · American Journal of Hematology / Oncology® · Cited by 2

Biology and Genomics of LCH and Related Disorders

Rollins, B. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-59632-7_2 · Cited by 2

Integrative multi-omic analysis of NLRP3 inflammasome dysregulation and subtyping for personalized treatment in acute myeloid leukemia

Zhang, H., Yang, L., Liu, Y., Wang, D., Shi, L., & Tian, C. (2025) · Discover Oncology · doi:10.1007/s12672-025-02383-9 · Cited by 1

Metabolic alterations in multiple myeloma and extramedullary disease- a novel niche of therapeutic targets

Purcell, E., Dowling, P., O’Gorman, P., & Bazou, D. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101360 · Cited by 1

In silico evaluation of herbal inhibitors against AKT isoforms as potential anticancer agents

Öz, H. (2026) · Discover Chemistry. · doi:10.1007/s44371-025-00440-4 · Cited by 1

Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia

Kolosova, A., Mould, I. A., Pepper, C. J., Mitchell, S., Pepper, A. G. S., Ladikou, E. E., & Simoes, F. A. (2026) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s511758 · Cited by 1

A key to the quest?

Leleu, X. P. (2014) · Blood · doi:10.1182/blood-2014-08-593822 · Cited by 1

New drugs on the horizon. Treatment of myeloma in 2020, a perspective

Ludwig, H., Hilbe, W., & Zojer, N. (2015) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-014-0194-0 · Cited by 1

Treatment of Patients in Third Relapse and Beyond Including Double-Refractory Disease

Tremblay, D. A., Leng, S., & Chari, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-61872-2_6 · Cited by 1

Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy

Stamou, M. I., Chen, C. T., Wander, S. A., Supko, J. G., Juric, D., Bardia, A., & Wexler, D. J. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00428 · Cited by 1

The Role of PI3K/AKT/mTOR Inhibitors in the Treatment of Hematological Malignancies

Shen, Z., & Kelly, K. R. (2015) · Springer eBooks · doi:10.1007/978-2-8178-0492-7_7

Targeted Therapies in Mesothelioma

Urso, L., & Pasello, G. (2019) · Springer eBooks · doi:10.1007/978-3-030-16884-1_17

Regulation of Chaperone-Mediated Autophagy by PI3K Signaling

Ziemba, Z. (2020) · Deep Blue (University of Michigan)

Mutation-dependent treatment approaches for patients with complex multiple myeloma

Theodorakakou, F., Dimopoulos, M. A., & Kastritis, E. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1893605

Development of a 3D in Vitro Disease Model for Multiple Myeloma

Trujillo, S. C. (2022) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/186054

Pharmacologic Differentiation of Drugs Targeting the PI 3K‐ AKT ‐m TOR Signaling Pathway

Ahn, I. E., Brown, A. J. R., & Davids, M. S. (2023) · doi:10.1002/9781119819950.ch6

ผลยับยั้งของไซพริพีดินต่อการเปลี่ยนแปลงจากเซลล์เยื่อบุผิวไปเป็นเซลล์มีเซนไคม์ในเซลล์มะเร็งปอดชนิดไม่ใช่เซลล์เล็กผ่านวิถีของเอเคที

ตรีสุวรรณ, ส., & พงศ์เรขนานนท์, ว. (2017) · Chula Digiverse · doi:10.58837/chula.the.2017.652

ADiffGDA: Exploring Gene-Drug Associations via Adaptive Graph Diffusion Networks

Zhang, C., Fan, Y., Hu, X., Qian, Y., & Deng, L. (2024) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm62325.2024.10821876

Oxidative Kinetic Resolution of Alkyl-Substituted 1,2-Diamines

Kan, L., Xu, Z., Ji, Y., Liu, H., Liu, L., & Wang, G. (2025) · Organic Letters · doi:10.1021/acs.orglett.5c01875

AGDNGDA: Unraveling Drug-Associated Genes with Adaptive Graph Diffusion Networks

Hu, X., Zhang, C., Fan, Y., Wu, K., & Deng, L. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02276

AKT as a Therapeutic Target in Cancer

Myint, K. N., & Vivanco, I. (2025) · Current topics in microbiology and immunology · doi:10.1007/82_2025_334 · Cited by 1

Anti-tumour and associated metabolic effects of repurposed afuresertib and taxifolin for glioblastoma treatment

Chen, R., Gümüş, N., Jearranaiprepame, S., Whitby, A., Rahman, R., & Kim, D. (2025) · The Analyst · doi:10.1039/d5an00461f

Additional file 1 of Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

Hirano, M., Imai, Y., Kaito, Y., Murayama, T., Sato, K., Ishida, T., Yamamoto, J., Ito, T., Futami, M., Ri, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14303001

Additional file 2 of Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

Hirano, M., Imai, Y., Kaito, Y., Murayama, T., Sato, K., Ishida, T., Yamamoto, J., Ito, T., Futami, M., Ri, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14303004

Additional file 3 of Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

Hirano, M., Imai, Y., Kaito, Y., Murayama, T., Sato, K., Ishida, T., Yamamoto, J., Ito, T., Futami, M., Ri, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14303007

Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non–Hodgkin Lymphoma (CAPITAL)

Hodson, D. J., Shouse, G., Shin, H., Salar, A., Bobillo, S., Ribrag, V., Macpherson, N. A., Cordoba, R., Kim, J. S., Guidez, S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2239

Intégration de multiples approches omiques pour améliorer la prise en charge des patients atteints de cancer pédiatrique

Savary, C. (2020) · theses.fr (ABES) · doi:10.70675/c9668778z4218z4692z908fz449455de3a1e

Construction of a Neoantigen Prognostic Model for Gastric Adenocarcinoma Based on Multi-Omics Data Mining and the Design of mRNA Vaccines and Targeted Drugs

Liang, J., Xie, Z., Sun, Y., Tang, Y., Gul, S., Qi, Q., Pang, J., Chen, Y., Wang, H., Zhang, J., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177712

BindingDB Entry 50022618: Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt.

BindingDB (2025) · UC San Diego · doi:10.7270/q26q230q

BindingDB Entry 50021311: Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises.

BindingDB (2025) · UC San Diego · doi:10.7270/q20v8jd8

BindingDB Entry 50047487: Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.

BindingDB (2017) · UC San Diego · doi:10.7270/q2qj7k5k

Afuresertib Shows Activity Against Multiple Myeloma

Lawrence, L. (2014)

A key to the quest?

Leleu, X. P. (2014) · Blood · doi:10.1182/blood-2014-08-593822 · Cited by 1

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

Garcia‐Manero, G., Tibes, R., Kadia, T. M., Kantarjian, H. M., Arellano, M. L., Knight, E., Xiong, H., Qin, Q., Munasinghe, W. P., Roberts-Rapp, L. A., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0242-6 · Cited by 21

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Tolcher, A. W., Patnaik, A., Papadopoulos, K. P., Rasco, D. W., Becerra, C. R., Allred, A. J., Orford, K., Aktan, G., Ferron-Brady, G., Ibrahim, N., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2615-5 · Cited by 158

Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study

Spencer, A. G., Yoon, S., Harrison, S. J., Morris, S. R., Smith, D. A., Freedman, S. J., Brigandi, R. A., Oliff, A. I., Opalinska, J., & Chen, C. I. (2011) · Blood · doi:10.1182/blood.v118.21.1856.1856 · Cited by 16